Clopidogrel low response is associated with a significantly higher risk for ischemic
complications after percutaneous coronary intervention. Ticagrelor and prasugrel are more
potent platelet inhibitory drugs and both have been shown to significantly reduce ischemic
events as compared to clopidogrel. No direct comparison between ticagrelor and prasugrel in
terms of their antiplatelet efficacy exists. The aim of this study is to assess the
antiplatelet treatment efficacy of ticagrelor versus prasugrel over time in confirmed
clopidogrel low responders undergoing percutaneous coronary intervention.